Impact of addition of propofol to ED formulary.
OBJECTIVE
Access to propofol remains a challenge for many emergency physicians. This report examines changes in patient care after the introduction of propofol to an emergency department formulary.


METHODS
The Procedural Sedation in the Community Emergency Department registry is a prospective multicentered database of community emergency physician-directed procedural sedation cases. Medication selection and patient outcome were compared at a single Procedural Sedation in the Community Emergency Department registry study site before and after credentialing of emergency physicians for the use of propofol. Analysis was done through analysis of variance and χ(2) test.


RESULTS
Over a 36-month period, 573 patients were entered into the registry from the single study site, 255 before and 318 after propofol introduction. The percentage of propofol use increased from 26% of procedural sedation cases in the first 3 months of availability to 69% in the final 3 months analyzed. Before propofol use, 46% of cases were completed with a single agent compared with after propofol use, in which 66% were completed with a single agent (P < .001). Complications decreased from 9% of patients before propofol use to 3% of patients after propofol use (P < .05), whereas sedation failures decreased from 5.1% to 4.1% (P < .02).


CONCLUSIONS
Granted access to propofol, emergency physicians will preferentially use this medication over prior procedural sedation agents with fewer procedural sedation complications and greater procedural success.
Senula
Gary
G
Williamsport Medical Center, Williamsport, PA, USA.
Sacchetti
Alfred
A
Moore
Sandra
S
Cortese
Teena
T
D000293:Adolescent; D000328:Adult; D000368:Aged; D000704:Analysis of Variance; D016009:Chi-Square Distribution; D002648:Child; D004636:Emergency Service, Hospital / Q000706:statistics & numerical data*; D005260:Female; D005572:Formularies, Hospital as Topic; D006801:Humans; D006993:Hypnotics and Sedatives / Q000009:adverse effects / Q000600:supply & distribution* / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D015742:Propofol / Q000009:adverse effects / Q000600:supply & distribution* / Q000627:therapeutic use; D012042:Registries / Q000706:statistics & numerical data; D055815:Young Adult
D006993:Hypnotics and Sedatives; D015742:Propofol